Table 1. Demographics and baseline clinical characteristics.
| Characteristics | N = 213 |
|---|---|
| Age (years, mean±SD,) | 63.7±9.6 |
| Sex, n (%) | |
| Male | 97 (45.5%) |
| Female | 116 (54.5%) |
| Body mass index (kg/m2, mean±SD) | 25.1±3.9 |
| Genotype, n (%) | |
| 1a | 21 (9.9%) |
| 1b | 192 (90.1%) |
| Cirrhosis, n (%) | 116 (54.5%) |
| Hepatocellular carcinoma, n (%) | 18 (8.5%) |
| Fatty liver by sonography | 58(27.2%) |
| HBsAg presence, n (%) | 11(5.1%) |
| AST (U/L, mean±SD) | 81.3±55.8 |
| ALT (U/L, mean±SD) | 131.1±267.4 |
| Albumin (mg/dl, mean±SD) | 4.29±0.34 |
| Baseline HCV RNA(log IU/ml, mean±SD) | 5.99±0.75 |
| Platelet (103/mm3, mean±SD) | 140.2±67.4 |
| Fibrosis-4 index † (mean±SD) | 5.05±6.96 |
| Prothrombin time (INR, mean±SD) | 1.16±0.91 |
| Total Bilirubin (mg/dl, mean±SD) | 1.02±0.39 |
| Total cholesterol # (mg/dl mean±SD) | 167.7±31.5 |
| Triglyceride # (mg/dl, mean±SD) | 99.3±55.6 |
| Alpha-Fetoprotein (ng/ml, mean±SD) | 17.8±37.5 |
| Baseline liver stiffness (kPa, mean±SD) | 18.5±11.6 |
| Baseline CAP (dB/m, mean±SD) | 228.0±35.6 |
HBsAg, hepatitis B virus surface antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CAP, controlled attenuation parameter
†: Fibrosis-4 index = [(Age * AST) / (PLT* (ALT)1/2)]
#: n = 155